INTERACTION OF SULFONAMIDE AND SULFONE COMPOUNDS WITH TOXOPLASMA-GONDII DIHYDROPTEROATE SYNTHASE

被引:59
作者
ALLEGRA, CJ
BOARMAN, D
KOVACS, JA
MORRISON, P
BEAVER, J
CHABNER, BA
MASUR, H
机构
[1] NIH,CTR CLIN,BETHESDA,MD 20892
[2] NIH,BIOMED ENGN & INSTRUMENTAT BRANCH,DIV RES SERV,BETHESDA,MD 20892
关键词
antimetabolites; enzymology; protozoan; sulfonamides;
D O I
10.1172/JCI114448
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Toxoplasma gondii is a common protozoan disease that often causes life-threatening disease, particularly among patients wih the acquired immunodeficiency syndrome. This study demonstrates that the dihydropteroate synthase in T. gondii is kinetically distinct from the enzyme characterized from other sources and can be highly purified with a high yield using sequential dye-affinity chromatography. Conditions have been identified that allow for stabilization of the purified enzyme, and its physical characteristics have been elucidated. The molecular weight of the native protein was 125,000 and the protein appeared to contain both dihydropteroate synthase and 6-hydroxymethyl-dihydropterin pyrophosphokinase activities. The sulfonamide class of compounds vary in inhibitory potency by more than three orders of magnitude. Sulfathiozole, sulfamethoxazole, and sulfamethazine, with 50% inhibitory concentrations (IC50's) of 1.7, 2.7, and 5.7 μM, respectively, represent the most potent of this class of inhibitors. Several sulfone analogues, including dapsone, were identified as highly potent inhibitors with IC50's <1 μM. The results of these cell-free experiments were corroborated by investigating the metabolic inhibition produced by the various inhibitors in intact organisms. The qualitative and quantitative relations among the inhibitors were preserved in both the cell-free and intact cell assay systems. These studies suggest that the sulfones may be important therapeutic agents for the treatment of toxoplasmosis.
引用
收藏
页码:371 / 379
页数:9
相关论文
共 34 条
[1]  
ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478
[2]  
ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720
[3]   POTENT INVITRO AND INVIVO ANTITOXOPLASMA ACTIVITY OF THE LIPID-SOLUBLE ANTIFOLATE TRIMETREXATE [J].
ALLEGRA, CJ ;
KOVACS, JA ;
DRAKE, JC ;
SWAN, JC ;
CHABNER, BA ;
MASUR, H .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (02) :478-482
[4]   Studies in chemotherapy. VII. A theory of the relation of structure to activity of sulfanilamide type compounds [J].
Bell, PH ;
Roblin, RO .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1942, 64 :2905-2917
[5]  
Biocca E, 1942, ARQ BIOL SAO PAULO, V26, P107
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   QUANTITATIVE STRUCTURE ACTIVITY ANALYSIS IN DIHYDROPTEROATE SYNTHASE INHIBITION BY SULFONES - COMPARISON WITH SULFANILAMIDES [J].
DEBENEDETTI, PG ;
IAROSSI, D ;
MENZIANI, C ;
CAIOLFA, V ;
FRASSINETI, C ;
CENNAMO, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (03) :459-464
[8]   SIMULTANEOUS ANALYSIS OF FAMILIES OF SIGMOIDAL CURVES - APPLICATION TO BIOASSAY, RADIOLIGAND ASSAY, AND PHYSIOLOGICAL DOSE-RESPONSE CURVES [J].
DELEAN, A ;
MUNSON, PJ ;
RODBARD, D .
AMERICAN JOURNAL OF PHYSIOLOGY, 1978, 235 (02) :E97-E102
[9]   NEWER KNOWLEDGE OF THE CHEMOTHERAPY OF TOXOPLASMOSIS [J].
EYLES, DE .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1956, 64 (02) :252-267